HCV among Male Injection Drug Users and their Female Partners in Almaty, Kazakhstan: Implications for HCV Treatment and Prevention 

Authors

  • Nabila El-Bassel Global Health Research Center of Central Asia, Columbia University, New York City, 1255 Amsterdam Avenue, New York, NY 10027, USA
  • Louisa Gilbert
  • Chris Beyrer Center for Public Health and Human Rights, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St #5041, Baltimore, MD 21205, USA
  • Assel Terlikbayeva Global Health Research Center of Central Asia, Columbia University, 102 Luganskogo St, Ap.1, Medeu District, Almaty 050059, Kazakhstan
  • Elwin Wu Global Health Research Center of Central Asia, Columbia University, New York City, 1255 Amsterdam Avenue, New York, NY 10027, USA
  • Xin Ma
  • Mingway Chang
  • Stacey A. Shaw
  • Baurzhan Zhussupov Global Health Research Center of Central Asia, Columbia University, 102 Luganskogo St, Ap.1, Medeu District, Almaty 050059, Kazakhstan
  • Tim Hunt Global Health Research Center of Central Asia, Columbia University, New York City, 1255 Amsterdam Avenue, New York, NY 10027, USA
  • Sholpan Primbetova Global Health Research Center of Central Asia, Columbia University, 102 Luganskogo St, Ap.1, Medeu District, Almaty 050059, Kazakhstan
  • Yelena Rozental

DOI:

https://doi.org/10.12970/2309-0529.2014.02.01.1

Keywords:

 HCV, Injection drug use, Central Asia, HIV, Kazakhstan.

Abstract

 HCV infection is a serious concern among people who inject drugs. Despite imposing a major disease burden in countries with high rates of injection drug use such as Kazakhstan, other Central Asian and East Asian countries, Eastern Europe, and Russia, HCV remains an understudied issue. This study includes 728 individuals (364 couples) from Almaty, Kazakhstan, where at least one member of the dyad reported recent injection drug use. Participants were recruited to participate in a couple-based HIV prevention study. We examine the prevalence of HCV and co-infections between HCV and HIV, correlates of HCV, and the association between HCV prevalence and sexual behaviors after adjusting for non-injection illicit drug use, unsafe injection behaviors, and socio-demographic characteristics. Of the total sample, 90.2% of people who had ever injected drugs were diagnosed HCV positive and 15.5% of those who did not report injecting drugs were HCV positive. The prevalence of HIV and HCV co-infection among the total sample was 20.7%. In the multivariate analysis, having sex while high on alcohol and/or drugs was associated with HCV after adjusting for unsafe injection practices, non-injection drug use, and socio-demographic characteristics (PR=1.20; 95% CI=1.04, 1.39). The high rates of HCV and co-infection of HIV and HCV found in the study underscore the need for attention to HCV testing and treatment among people who inject drugs in Kazakhstan and their sex partners. 

References


[1] Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-83. http://dx.doi.org/10.1016/S0140-6736(11)61097-0
[2] Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007; 18: 352-8. http://dx.doi.org/10.1016/j.drugpo.2007.04.004
[3] Hagan H. Hepatitis C virus transmission dynamics in injection drug users. Subst Use Misuse 1998; 33: 1197-12. http://dx.doi.org/10.3109/10826089809062214
[4] Zhang T, Li Y, Lai JP, et al. Alcohol potentiates hepatitis C virus replicon expression. Hepatology 2003; 38: 57-65. http://dx.doi.org/10.1053/jhep.2003.50295
[5] Liu P, Xiang K, Tang H, et al. Molecular epidemiology of human immunodeficiency virus type 1 and hepatitis C virus in former blood donors in central China. AIDS Res Hum Retroviruses 2008; 24: 1-6. http://dx.doi.org/10.1089/aid.2007.0144
[6] Aitken CK, Lewis J, Tracy SL, et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 2008; 48: 1746-52. http://dx.doi.org/10.1002/hep.22534
[7] Walsh N, Maher L. HIV and viral hepatitis C coinfection in people who inject drugs implications of new direct acting antivirals for hepatitis C virus treatment. Curr Opin HIV AIDS 2012; 7: 339-44. http://dx.doi.org/10.1097/COH.0b013e328354131e
[8] UNAIDS. UNAIDS Report on the Global AIDS Epidemic. Switzerland: UNAIDS, 2010 Contract No.: Report.
[9] Hagan H, Thiede H, Des Jarlais DC. HIV/hepatitis C virus coinfection in drug users: risk behavior and prevention. AIDS 2005; 19: S199-207.
[10] CDC. Hepatitis C FAQs for the Public: Centers for Disease Control and Prevention; 2012 [cited 2013 Web Page]. Available from: http://www.cdc.gov/hepatitis/c/cfaq.htm
[11] Gyarmathy VA, Neaigus A, Miller M, Friedman SR, Des Jarlais DC. Risk correlates of prevalent HIV, hepatitis B virus, and hepatitis C virus infections among noninjecting heroin users. J Acquir Immune Defic Syndr 2002; 30: 448-56.
[12] Howe CCJ, Fuller CM, Ompad DC, et al. Association of sex, hygiene and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York City. Drug Alcohol Depend 2005; 79: 389-95. http://dx.doi.org/10.1016/j.drugalcdep.2005.03.004
[13] Tortu S, McMahon JM, Pouget ER, Hamid R. Sharing of noninjection drug-use implements as a risk factor for hepatitis C. Subst Use Misuse 2004; 39: 211-24. http://dx.doi.org/10.1081/JA-120028488
[14] Roy K, Hay G, Andragetti R, Taylor A, Goldeberg D, Wiessing L. Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol Infect 2002; 129: 577-85. http://dx.doi.org/10.1017/S0950268802007902
[15] Ti L, Buxton J, Wood E, Zhang R, Montaner J, Kerr T. Difficulty accessing crack pipes and crack pipe sharing among people who use drugs in Vancouver, Canada. Subst Abuse Treat Prev Policy 2011; 6: 34. http://dx.doi.org/10.1186/1747-597X-6-34
[16] Ivsins A, Roth E, Nakamura N, Krajden M, Fischer B. Uptake, benefits of and barriers to safer crack use kit (SCUK) distribution programmes in Victoria, Canada—A qualitative exploration. Int J Drug Policy 2011; 22: 292-300. http://dx.doi.org/10.1016/j.drugpo.2011.05.005
[17] Mehta SH, Genberg BL, Astemborski J, et al. Limited uptake of Hepatitis C treatment among injection drug users. J Community Health 2008; 33: 126-33. http://dx.doi.org/10.1007/s10900-007-9083-3
[18] Beyrer C, Patel Z, Stachowiak JA, et al. Characterization of the Emerging HIV Type 1 and HCV Epidemics among Injecting Drug Users in Dushanbe, Tajikistan. AIDS Res Hum Retroviruses 2009; 25: 853-60. http://dx.doi.org/10.1089/aid.2008.0206
[19] Howe CJ, Fuller CM, Ompad DC, et al. Association of sex, hygiene and drug equipment sharing with hepatitis C virus infection among non-injecting drug users in New York City. Drug Alcohol Depend 2005; 79: 389-95. http://dx.doi.org/10.1016/j.drugalcdep.2005.03.004
[20] Vandelli C, Renzo F, Romano L, et al. Lack of evidence of sexual transmission of Hepatitis C among monogamous couples: Results of a 10-year prospective follow-up study. Am J Gastroenterol 2004; 99: 855-9. http://dx.doi.org/10.1111/j.1572-0241.2004.04150.x
[21] Terrault NA, Shiffman ML, Lok ASF, et al. A2ALL study group. Outcomes in hepatitis C virus–infected recipients of living donor vs. deceased donor liver transplantation. Liver Transpl 2007; 13: 122-9. http://dx.doi.org/10.1002/lt.20995
[22] Alter MJ. Epidemiology of hepatitis C virus infection. World J Gasteroenterol 2007; 13: 2436-41.
[23] Desenclos JC. The challenge of hepatitis C surveillance in Europe. Euro Surveill 2003; 8: 99-100.
[24] Williams I. Epidemiology of hepatitis C in the United States. Am J Med 1999; 107: 2S-9S. http://dx.doi.org/10.1016/S0002-9343(99)00373-3
[25] Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001; 34: 180-7. http://dx.doi.org/10.1053/jhep.2001.25759
[26] Santantonio T, Medda E, Ferrari C, et al. Risk factors and outcome among a large patient cohort with community acquired acute Hepatitis C in Italy. Clin Infect Dis 2006; 43: 1154-9. http://dx.doi.org/10.1086/507640
[27] Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology 2003; 37(1): 60-4. http://dx.doi.org/10.1053/jhep.2003.50019
[28] Kamal SM. Acute Hepatitis C: a systematic review. Am J Gastroenterol 2008; 103: 1283-97. http://dx.doi.org/10.1111/j.1572-0241.2008.01825.x
[29] Butsashvili M, Tsertsvadze T, McNutt LA, Kamkamidze G, Gvetadze RJ, Badridze N. Prevalence of hepatitis B, hepatitis C, syphilis and HIV in Georgian blood donors. Eur J Epidemiol 2001; 17: 693-5. http://dx.doi.org/10.1023/A:1015566132757
[30] Thomas DL, Zenilman JM, Alter HJ, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore--an analysis of 309 sex partnerships. J Infect Dis 1995; 171: 768- 75. http://dx.doi.org/10.1093/infdis/171.4.768
[31] Chakrapani V, Newman P, Shunmugam M, Dubrow R. Social-structural contexts of needle and syringe sharing behaviours of HIV-positive injecting drug users in Manipur, India: a mixed methods investigation. Harm Reduct J 2011; 8: 9. http://dx.doi.org/10.1186/1477-7517-8-9
[32] Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: Why individual, structural, and combination approaches are needed. Lancet 2010; 376: 285-301. http://dx.doi.org/10.1016/S0140-6736(10)60742-8
[33] Strathdee SA, Lozada R, Martinez G, et al. Social and structural factors associated with HIV Infection among female sex workers who inject drugs in the Mexico-US border region. PloS One 2011; 6: e19048.
[34] Strathdee SA, Stockman JK. Epidemiology of HIV Among Injecting and Non-injecting Drug Users: Current Trends and Implications for Interventions. Curr HIV/AIDS Rep 2010; 7: 99-106. http://dx.doi.org/10.1007/s11904-010-0043-7
[35] Wechsberg WM, Luseno WK. The need for culturally appropriate, gender-specific global HIV prevention efforts with vulnerable women. J Prev Interv Community 2010; 38: 85-8. http://dx.doi.org/10.1080/10852351003640559
[36] Auerbach JD, Parkhurst JO, Caceres CF. Addressing social drivers of HIV/AIDS for the long-term response: Conceptual and methodological considerations. Glob Public Health 2011; 6(Suppl 3): S293-309.
[37] Epperson MW, Khan MR, Miller DP, Perron BE, El-Bassel N, Gilbert L. Assessing criminal justice involvement as an indicator of human immunodeficiency virus risk among women in methadone treatment. J Subst Abuse Treat 2010; 38: 375-83. http://dx.doi.org/10.1016/j.jsat.2010.03.004
[38] Finkelstein R, Netherland J, Sylla L, Gourevitch MN, Cajina A, Cheever L. Policy implications of integrating buprenorphine/naloxone treatment and HIV care. J Acquir Immune Defic Syndr 2011; 56: S98-S104.
[39] Jablonowska E, Malolepsza E. Causes of antiretroviral therapy discontinuation in the outpatient HIV/AIDS clinic in Lodz. Przegl Epidemiol 2010; 64: 491-5.
[40] Tapp C, Milloy MJ, Kerr T, et al. Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare. BMC Infect Dis 2011; 11: 86. http://dx.doi.org/10.1186/1471-2334-11-86
[41] Boltaev A, Deryabina A, Kusainov A, Howard A. Evaluation of a pilot medication-assisted therapy program in Kazakhstan: successes, challenges, and opportunities for scaleup. Adv Prev Med 2012; 2012: 308793. http://dx.doi.org/10.1155/2012/308793
[42] Straus MA. Measuring intrafamily conflict and violence: the conflict tactics (CT) scales. J Marriage Fam 1979; 41: 75-88. http://dx.doi.org/10.2307/351733
[43] Booth RE, Mikulich-Gilbertson SK, Brewster JT, Salomonsen-Sautel S, Semerik O. Predictors of self-reported HIV infection among drug injectors in Ukraine. J Acquir Immune Defic Syndr 2004; 35: 82-8. http://dx.doi.org/10.1097/00126334-200401010-00012
[44] Needle R, Fisher DG, Weatherby N, et al. Reliability of selfreported HIV risk behaviors of drug users. Psychol Addict Behav 1995; 9: 242-50. http://dx.doi.org/10.1037/0893-164X.9.4.242
[45] Young H, Moyes A, Seagar L, McMillan A. Novel recombinant-antigen enzyme immunoassay for serological diagnosis of syphilis. J Clin Microbiol 1998; 36: 913-7.
[46] Higgs P, Dwyer R, Duong D, et al. Heroin–gel capsule cocktails and groin injecting practices among ethnic Vietnamese in Melbourne, Australia. Int J Drug Policy 2009; 20: 340-6. http://dx.doi.org/10.1016/j.drugpo.2008.05.001
[47] Des Jarlais DC, Diaz T, Perlis T, et al. Variability in the incidence of human immunodeficiency virus, hepatitis B cirus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol 2003; 157: 467- 71. http://dx.doi.org/10.1093/aje/kwf222

Downloads

Published

2014-04-05

Issue

Vol. 2 No. 1 (2014)

Section

Articles